234 related articles for article (PubMed ID: 31813444)
1. Adverse drug reactions in tuberculosis and management.
Prasad R; Singh A; Gupta N
Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reactions & drug interactions in MDR-TB patients.
Gupta A; Kumar V; Natarajan S; Singla R
Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
[TBL] [Abstract][Full Text] [Related]
3. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
[TBL] [Abstract][Full Text] [Related]
4. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
[TBL] [Abstract][Full Text] [Related]
5. Profile of adverse drug reactions in drug resistant tuberculosis from Punjab.
Bhushan B; Chander R; Kajal NC; Ranga V; Gupta A; Bharti H
Indian J Tuberc; 2014 Oct; 61(4):318-24. PubMed ID: 25675695
[TBL] [Abstract][Full Text] [Related]
6. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
[TBL] [Abstract][Full Text] [Related]
7. Design of the anti-tuberculosis drugs induced adverse reactions in China National Tuberculosis Prevention and Control Scheme Study (ADACS).
Xia YY; Hu DY; Liu FY; Wang XM; Yuan YL; Tu DH; Chen YX; Zhou L; Zhu LZ; Gao WW; Wang HY; Chen da F; Yang L; He PP; Li XT; He YJ; Sun F; Zhan SY
BMC Public Health; 2010 May; 10():267. PubMed ID: 20492672
[TBL] [Abstract][Full Text] [Related]
8. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature.
Kargar M; Mansouri A; Hadjibabaie M; Javadi M; Radfar M; Gholami K
Expert Opin Drug Saf; 2014 Jul; 13(7):875-91. PubMed ID: 24935479
[TBL] [Abstract][Full Text] [Related]
9. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
10. Frequency of adverse events observed with second-line drugs among patients treated for multidrug-resistant tuberculosis.
Prasad R; Singh A; Srivastava R; Hosmane GB; Kushwaha RA; Jain A
Indian J Tuberc; 2016 Apr; 63(2):106-14. PubMed ID: 27451820
[TBL] [Abstract][Full Text] [Related]
11. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
12. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
[TBL] [Abstract][Full Text] [Related]
13. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and Risk Factors Associated with Adverse Drug Reactions among Previously Treated Tuberculosis Patients in China.
Han XQ; Pang Y; Ma Y; Liu YH; Guo R; Shu W; Huang XR; Ge QP; DU J; Gao WW
Biomed Environ Sci; 2017 Feb; 30(2):139-142. PubMed ID: 28292352
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions and treatment outcome analysis of DOTS-plus therapy of MDR-TB patients at district tuberculosis centre: A four year retrospective study.
Dela AI; Tank NKD; Singh AP; Piparva KG
Lung India; 2017; 34(6):522-526. PubMed ID: 29098997
[TBL] [Abstract][Full Text] [Related]
16. Incidence and outcomes of adverse drug reactions to first-line anti-tuberculosis drugs and their effects on the quality of life: A multicenter prospective cohort study.
Choi H; Park HA; Hyun IG; Kim JH; Hwang YI; Jang SH; Sim YS; Shin TR; Ko Y; Ban GY; Hong JY; Lee CY; Lee MG; Choi JH
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1153-1163. PubMed ID: 35909258
[TBL] [Abstract][Full Text] [Related]
17. Direct costs of managing adverse drug reactions during rifampicin-resistant tuberculosis treatment in South Africa.
Schnippel K; Firnhaber C; Berhanu R; Page-Shipp L; Sinanovic E
Int J Tuberc Lung Dis; 2018 Apr; 22(4):393-398. PubMed ID: 29562986
[TBL] [Abstract][Full Text] [Related]
18. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
19. Clinical research in the treatment of tuberculosis: current status and future prospects.
Chang KC; Yew WW; Sotgiu G
Int J Tuberc Lung Dis; 2015 Dec; 19(12):1417-27. PubMed ID: 26614181
[TBL] [Abstract][Full Text] [Related]
20. Assessing the prevalence and effect of adverse drug reactions among patients receiving first line anti-tubercular medicines in the Tamale Teaching Hospital, Ghana.
Amalba A; Bugri AA
Pan Afr Med J; 2021; 38():191. PubMed ID: 33995797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
